Xalud Therapeutics, Inc.

San Francisco, CA 94110

SBIR Award Summary

Total Number of Awards 7
Total Value of Awards $3.54MM
First Award Date 06/15/11
Most Recent Award Date 09/01/14

Key Personnel

Last Name Name Awards Contact
Chavez Raymond A. Chavez 7 Message

7 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-08-235
Budget: 09/01/14 - 08/31/15

DESCRIPTION (provided by applicant): The overall aim of this proposal is the acquisition of the remaining pre-clinical data required for submission of an Investigational New Drug (IND) application for a human clinical trial of XT-101 for the treatment of neuropathic pain. XT-101 is an encapsulated formulation of an expression plasmid DNA encodin...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 02/01/14 - 01/31/15

DESCRIPTION (provided by applicant): Xalud Therapeutics proposes to evaluate the applicability of its novel and potent anti-inflammatory therapy, XT-101, for the treatment of motor impairment, gait disorders, and neuropathic pain in degenerative and inflammatory autoimmune rodent models of multiple sclerosis (MS). XT-101 is a non-viral form of g...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-08-235
Budget: 09/01/13 - 08/31/14

DESCRIPTION (provided by applicant): The overall aim of this proposal is the acquisition of the remaining pre-clinical data required for submission of an Investigational New Drug (IND) application for a human clinical trial of XT-101 for the treatment of neuropathic pain. XT-101 is an encapsulated formulation of an expression plasmid DNA encodin...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-08-235
Budget: 09/01/13 - 08/31/14

DESCRIPTION (provided by applicant): The overall aim of this proposal is the acquisition of the remaining pre-clinical data required for submission of an Investigational New Drug (IND) application for a human clinical trial of XT-101 for the treatment of neuropathic pain. XT-101 is an encapsulated formulation of an expression plasmid DNA encodin...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 02/15/13 - 01/31/14

DESCRIPTION (provided by applicant): Xalud Therapeutics proposes to evaluate the applicability of its novel and potent anti-inflammatory therapy, XT-101, for the treatment of motor impairment, gait disorders, and neuropathic pain in degenerative and inflammatory autoimmune rodent models of multiple sclerosis (MS). XT-101 is a non-viral form of g...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-08-235
Budget: 06/01/12 - 05/31/13

DESCRIPTION (provided by applicant): The overall aim of this proposal is the acquisition of the remaining pre-clinical data required for submission of an Investigational New Drug (IND) application for a human clinical trial of XT-101 for the treatment of neuropathic pain. XT-101 is an encapsulated formulation of an expression plasmid DNA encodin...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-08-235
Budget: 06/15/11 - 05/31/12

DESCRIPTION (provided by applicant): The overall aim of this proposal is the acquisition of the remaining pre-clinical data required for submission of an Investigational New Drug (IND) application for a human clinical trial of XT-101 for the treatment of neuropathic pain. XT-101 is an encapsulated formulation of an expression plasmid DNA encodin...